Fig. 5: Modi-2 SNAPvax vaccination mediates tumour therapy. | npj Vaccines

Fig. 5: Modi-2 SNAPvax vaccination mediates tumour therapy.

From: Modi-2 a vaccine stimulating CD4 responses to homocitrullinated self epitopes as therapy for solid cancers

Fig. 5

HHDII/DP4 transgenic (A, B) or Balb/c (C–G) mice were injected with 1 x 105 B16 HHDII/iDP4 (A, B), 1.75 x 104 CT26 (C and D) or 5 × 103 4T1 (E–G) tumour cells respectively on day 1 followed by immunisation with 4nmol Modi-2 peptides in CpG/MPLA or 4nmol of Modi-2 SNAPvax on days 4, 11 and 18 (A, B) or days 4, 8 and 11 (C–G). Overall survival (OS) and tumour growth monitored (n ≥ 5). Numbers on tumour growth curves represent the number of tumour free (TF) mice out of the total. Survival analysed using LogRank test. (G), Tumours from 4T1 model disaggregated and stained ex vivo for CD45, CD8, CD4 infiltrate and MHCII expression. Representative tumour examples and histograms of averages (n > 3) with error bars of standard deviations are shown.

Back to article page